Observation of the Short-term Effcacy of Gemcitabine, Paclitaxel plus Cisplatin in the Treatment of Advanced Urothelial Carcinoma_West China Medical Journal

Authors：

 HEJian-ping , CHENYe , GUOChun-hong , LUOWu-xia , LICong ,  LIUJi-yan

Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

LIUJi-yan, Email: liujiyan1972@163.com.cn

Keywords：

Gemcitabine; Taxol; Cisplatin; Advanced urothelial carcinoma

DOI：

10.7507/1002-0179.20150353

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the efficacy and toxicity of gemcitabine, paclitaxel plus cisplatin (GTP) chemotherapy for advanced urothelial carcinoma in China. Methods Ten patients with advanced urothelial carcinoma who underwent GTP chemotherapy regimens were collected from February to July 2014 in our hospital. According to solid tumor curative effect evaluation standard 1.1, we evaluated the clinical effcacy and collected the adverse reactions. Results Ten patients with advanced urothelial carcinoma accepted first-line chemotherapy using GTP chemotherapy regimens. There was 1 case of complete remission, 4 cases of partial response, 3 stable cases, and 2 progressive cases. Adverse reactions of degree Ⅲ were mainly of hematology toxicity, including 5 cases of leukocytes and neutrophils reduction, and 1 case of anemia. The remaining adverse reactions included gastrointestinal reaction, hair loss, and abnormal renal function. Conclusion GTP chemotherapy regimen is a promising treatment for advanced urothelial carcinoma.

Citation： HEJian-ping, CHENYe, GUOChun-hong, LUOWu-xia, LICong, LIUJi-yan. Observation of the Short-term Effcacy of Gemcitabine, Paclitaxel plus Cisplatin in the Treatment of Advanced Urothelial Carcinoma. West China Medical Journal, 2015, 30(7): 1226-1229. doi: 10.7507/1002-0179.20150353 Copy

1.	Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer[J]. Semin in Oncol, 2012, 39(5):598-607.
2.	Stadler WM, Kuzel T, Roth B, et al. A phase Ⅱ study of singleagent gemcitabine in previously untreated patients with metastatic urothelial cancer[J]. J Clin Oncol, 1997, 15(11):3394-3398.
3.	Greene FL, PageDL, Fleming ID, et al. AJCC Cancer Staging Manual[M]. 6th ed. AJCC New York, Berlin, Heidelberg:SpringerVerlag, 2002.
4.	Sternberg CN, Yagoda A, Scher HL, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium[J]. J Urol, 1985, 133(3):403-407.
5.	Sternberg CN. A critical review of the management of bladder cancer[J]. Crit Rev Oncol Hematol, 1999, 31(3):197-207.
6.	Von der Maase H, Hanse SW, Roberts JT, et al. Gemcitabine and cispatin in advanced or metastatic bladder cancer:resuits of a large randomized multicenter, multinational multicenter, phase Ⅲ study[J]. J Clin Oncol, 2000, 18(17):3068-3077.
7.	Sternberg CN, De Mulder P, Schornagel JH, et al. Seven year update of EORTC phase Ⅲ trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors[J]. Eur J Cancer, 2006, 42(1):50-54.
8.	Bellmunt J, von der Masse H, Mead G, et al. Randomized phase Ⅲ study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or mestastatic urothelial cancer without prior systemic therapy; EORTC intergroup study 30987[J]. J Clin Oncol, 2012, 30(10):1107-1113.

1. Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer[J]. Semin in Oncol, 2012, 39(5):598-607.
2. Stadler WM, Kuzel T, Roth B, et al. A phase Ⅱ study of singleagent gemcitabine in previously untreated patients with metastatic urothelial cancer[J]. J Clin Oncol, 1997, 15(11):3394-3398.
3. Greene FL, PageDL, Fleming ID, et al. AJCC Cancer Staging Manual[M]. 6th ed. AJCC New York, Berlin, Heidelberg:SpringerVerlag, 2002.
4. Sternberg CN, Yagoda A, Scher HL, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium[J]. J Urol, 1985, 133(3):403-407.
5. Sternberg CN. A critical review of the management of bladder cancer[J]. Crit Rev Oncol Hematol, 1999, 31(3):197-207.
6. Von der Maase H, Hanse SW, Roberts JT, et al. Gemcitabine and cispatin in advanced or metastatic bladder cancer:resuits of a large randomized multicenter, multinational multicenter, phase Ⅲ study[J]. J Clin Oncol, 2000, 18(17):3068-3077.
7. Sternberg CN, De Mulder P, Schornagel JH, et al. Seven year update of EORTC phase Ⅲ trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors[J]. Eur J Cancer, 2006, 42(1):50-54.
8. Bellmunt J, von der Masse H, Mead G, et al. Randomized phase Ⅲ study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or mestastatic urothelial cancer without prior systemic therapy; EORTC intergroup study 30987[J]. J Clin Oncol, 2012, 30(10):1107-1113.

Previous Article
A Clinical study on the Application of Tranexamic Acid in Posterior Lumbar Fusion
Next Article
Factors Associated with Complications in Patients with Pheochromocytoma:A Retrospective Analysis

West China Medical Journal

Observation of the Short-term Effcacy of Gemcitabine, Paclitaxel plus Cisplatin in the Treatment of Advanced Urothelial Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content